Quo vadis dialysis membrane?
The development of dialysis membranes is closely related to the development of dialysis as a routine therapy for patients with kidney failure. Without having membranes and dialyzers available as commodity products, the treatment of more than 1 million uremic patients worldwide would be impossible. Several transition periods can be identified: a change in membrane geometry from flat sheet to capillaries, a shift in market appreciation from cellulose to synthetic polymers, and from low-flux to high-flux dialyzers. This shift is supported by the notion that convective therapies using high-flux membranes allow the removal of large-molecular-weight solutes. From a historical background, three eras of perception can be identified for both membrane and dialysis development. First, the period of survival when nephrologists had to focus on techniques for blood access and availability of membranes. Second, the period of issues dedicated to rather specific features of membranes and dialysis therapy such as dose of dialysis, reuse, sterilization, and membrane biocompatibility. And third, the period of quality tops this sequence with a complicated approach: the principal area of interest from the medical community has switched to issues such as quality of life, morbidity, mortality, therapy standards, and cost-effectiveness. New membrane developments should focus on this situation.
Vienken
Joerg
J
Fresenius Medical Care, Bad Homburg, Germany. joerg.vienken@fmc-ag.de
Bowry
Sudhir
S
D001672:Biocompatible Materials; D004867:Equipment Design; D006801:Humans; D007676:Kidney Failure, Chronic / Q000628:therapy; D008567:Membranes, Artificial; D006435:Renal Dialysis
D001672:Biocompatible Materials; D008567:Membranes, Artificial